文献速递头颈外科

Wnt-β-连环蛋白通路小分子抑制剂CWP232291在唾液腺腺样囊性癌临床前模型中抑制肿瘤生长

The Small Molecule Inhibitor of the Wnt-β-Catenin Pathway, CWP232291, Inhibits Tumor Growth in Preclinical Models of Salivary Gland Adenoid Cystic Carcinoma.
PubMed 文献 · Head Neck · 2025-07-17

本研究评估首创新小分子抑制剂CWP232291靶向Wnt-β-连环蛋白通路对唾液腺腺样囊性癌(ACC)的细胞毒和抗肿瘤作用。免疫组化显示β-连环蛋白高表达与ACC患者总生存期缩短相关;体外实验显示ACC细胞系对CWP232291敏感;体内实验显示CWP232291在细胞系移植瘤和患者来源移植瘤模型中均减弱肿瘤生长。

要点

  • β-连环蛋白高表达与ACC患者总生存期缩短相关
  • ACC细胞系MDA-ACC-01和UM-HACC-2A对CWP232291敏感
  • CWP232291在细胞系移植瘤和PDX模型中均减弱肿瘤生长

核心结论

  • 异常Wnt-β-连环蛋白信号可能在ACC发病机制中起积极作用,CWP232291抑制该通路可能具有治疗潜力,是值得进一步研究的有前景方向。

研究设计与样本

  • 研究采用ACC患者肿瘤微阵列和患者来源移植瘤(PDX),通过免疫组化、RNA-seq和qRT-PCR分析β-连环蛋白。

主要发现

  • 免疫组化分析显示β-连环蛋白高表达与ACC患者总生存期缩短相关。
  • Wnt-β-连环蛋白通路相关基因在PDX样本中富集。
  • 使用MDA-ACC-01和UM-HACC-2A细胞系的体外细胞毒性和生化实验显示ACC细胞对CWP232291敏感。
  • CWP232291治疗在细胞系移植瘤和PDX模型中均减弱体内肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salivary gland adenoid cystic carcinoma (ACC) is a rare and challenging form of head and neck cancer, particularly difficult to treat once it progresses to recurrent or metastatic disease. In this study, we evaluate the cytotoxicity and anti-tumorigenic effects of CWP232291, a first-in-class small molecule inhibitor targeting the Wnt-β-catenin signaling pathway. METHODS: Tumor microarrays of ACC patients and patient-derived xenografts (PDX) were evaluated by immunohistochemistry, RNA-seq, and qRT-PCR analysis for β-catenin. The effects of CWP232291 were determined by cytotoxic, qRT-PCR, and immunoblotting analysis. In vivo anti-tumorigenic effects of CWP232291 were evaluated using cell line xenograft and PDX models. RESULTS: Immunohistochemistry analysis revealed that high β-catenin expression correlated with reduced overall survival in ACC patients. Expression of genes involved in the Wnt-β-catenin pathway was enriched in PDX samples. In vitro cytotoxicity and biochemical assays using MDA-ACC-01 and UM-HACC-2A cell lines revealed that ACC cells were susceptible to CWP232291. Furthermore, CWP232291 treatment attenuated in vivo tumor growth in both cell line xenograft and PDX models. CONCLUSIONS: Abnormal Wnt-β-catenin signaling may play an active role in ACC pathogenesis, and its inhibition by CWP232291 may offer therapeutic potential, representing a promising avenue for further investigation.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Humtsoe JO, Keam B, Kim HS, et al. The Small Molecule Inhibitor of the Wnt-β-Catenin Pathway, CWP232291, Inhibits Tumor Growth in Preclinical Models of Salivary Gland Adenoid Cystic Carcinoma. Head Neck. 2025. PMID: 40671681. doi:10.1002/hed.28249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。